| Identification | Back Directory | [Name]
2-Chloro-7-(2-deoxy-4-C-ethynyl-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | [CAS]
1810869-23-8 | [Synonyms]
2-Chloro-7-(2-deoxy-4-C-ethynyl-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 2-chloro-7-(2-deoxy-4-C-ethynyl-β-D-erythro-pentofuranosyl)- | [Molecular Formula]
C13H13ClN4O3 | [MOL File]
1810869-23-8.mol | [Molecular Weight]
308.72 |
| Hazard Information | Back Directory | [Uses]
MK-8527 is an orally active HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI) with antiviral activity. MK-8527 has a similar inhibitory mechanism to ISL (HY-104012)[1][2][3][4]. | [References]
[1] Gillespie SW, et al. Islatravir: evaluation of clinical development for HIV and HBV. Expert Opin Investig Drugs. 2024 Feb;33(2):85-93. DOI:10.1080/13543784.2024.2305130
[2] Liu AY, et al. CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. Top Antivir Med. 2024 Jul 17;32(3):447-482. PMID:39142289
[3] Gunaratne SH, et al. CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets. Top Antivir Med. 2024 Aug 12;32(4):542-567. PMID:39746674
[4] Zhernov YV, et al. Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects. Pharmaceuticals (Basel). 2024 May 22;17(6):668. DOI:10.3390/ph17060668 |
|
| Company Name: |
NewCan Biotech Limited
|
| Tel: |
+86-0571-86912261 +86-15658003402 |
| Website: |
https://www.newcanbio.com/ |
|